NFKB1 and rheumatoid arthritis: In RA, neutrophil activation can be targeted by biologic DMARDs (bDMARDs), such as anti-TNF therapy, which has been demonstrated to decrease neutrophil membrane TNF expression and NF-κB activation (48).